Lyophilized Injectable Drugs Market size to exceed $740Bn by 2030

Lyophilized Injectable Drugs market size is estimated to reach over USD 740 billion by 2030, as per a new research report published by Global Market Insights Inc.
 

Extensive research and development initiatives in the pharmaceutical sector will foster the development of the industry. Leading market participants are scaling up research and commercialization of novel drugs to treat a wide range of diseases. Companies are also foraying into partnerships to accelerate drug discovery efforts. Additionally, the availability of contract research manufacturing services (CRAMS) has strengthened collaboration between major pharmaceutical companies aiming to boost operational capabilities for injectable drugs.
 

Lyophilized injectable anti-infective drugs gain traction with surging prevalence of infectious diseases

Anti-infective drug segment was worth USD 79 billion in 2021. Anti-infective medications encompass a broad range of drugs including antibacterial, antiviral, antiparasitic, and antifungal. The segment is anticipated to record lucrative growth on account of the increased transmission of infectious diseases such as influenza, herpes simplex virus, HIV, hepatitis virus, and others.
 

Browse key industry insights spread across 205 pages with 419 market data tables & 18 figures & charts from the report, “Lyophilized Injectable Drugs Market Size By Drug (Anti-infective, Anti-neoplastic, Anticoagulant, Hormones, Antiarrhythmic), By Indication (Autoimmune Diseases, Respiratory Diseases, Gastrointestinal Disorders, Oncology, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders), By Delivery (Prefilled Diluent Syringes, Multi-step Devices), By Packaging (Vials, Cartridges, Prefilled Devices), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/lyophilized-injectable-drugs-market
 

Rising preference for self-use drug delivery systems to promote multi-step devices adoption

Lyophilized injectable drugs market from multi-step devices segment is projected to expand at over 13% CAGR through 2030. Multi-step devices are one of the novel packaging solutions designed for lyophilized substances. This particular device offers an all-in-one option by combining solvent with the lyophilized substance. It is also a technologically advanced and complex structure as compared to vials and other devices. A multi-step device comprises of a glass body that is sectioned into two chambers via a central stopper and consists of a closure, plunger, and end-stopper.
 

Growing use of dual-chamber cartridge packaging in simple drug delivery systems

Lyophilized injectable drugs market from the cartridges segment is estimated to reach over USD 69 billion by 2030. The products offer a variety of benefits including enhanced accessibility, ease of use, and others. Single chamber and dual-chamber cartridges are ideal components in simple drug delivery or pen systems.
 

High risk of chronic disorders to highlight Asia Pacific market trends

Asia Pacific lyophilized injectable drugs market is projected to surpass USD 175 billion by 2030, with increasing incidences of chronic diseases. Notable economic concerns associated with the rising mortality rate in the region have propelled efforts to expand clinical trial capacities, particularly in the densely populated countries of APAC such as India, and China. Studies have found that 1 out of 10 Chinese adults have diabetes, estimating a continual escalation of the prevalence of chronic diseases in the country. As such, the development of novel drugs will pick up pace across the region.
 

New affordable products to foster lyophilized injectable drugs industry expansion

Bristol Myers Squibb, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Sanofi, Aurobindo Pharmaceuticals, Fresenius SE & Co. KGaA (Fresenius Kabi), Merck & Co., Inc, Zydus Group, Vetter Pharma, and Johnson & Johnson Services, Inc are some of the leading companies in the lyophilized injectable drugs industry.